Baidu
map

Nat Commun:奥希替尼配合耐药信号抑制明显改善EGFR突变型肺癌的预后

2020-09-19 xiaozeng MedSci原创

肺癌是全球范围内癌症相关死亡的主要原因之一,非小细胞肺癌(NSCLC)占肺癌的85%。包括抗PD-1抗体和抗PD-L1抗体在内的免疫检查点抑制剂(ICIs)已获准用于晚期NSCLC的治疗,且已证实该治

肺癌是全球范围内癌症相关死亡的主要原因之一,非小细胞肺癌(NSCLC)占肺癌的85%。包括抗PD-1抗体和抗PD-L1抗体在内的免疫检查点抑制剂(ICIs)已获准用于晚期NSCLC的治疗,且已证实该治疗策略甚至可以治愈该类患者。

奥希替尼(osimertinib)是第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),可选择性抑制突变型EGFR,如L858R、T790M突变以及第19号外显子缺失的EGFR。对于包括吉非替尼(gefitinib)和厄洛替尼(erlotinib)在内的经典EGFR-TKI难治愈性的携带EGFR T790M突变的NSCLC患者,奥希替尼治疗能够起到较为显著的效果。

AXL低表达肿瘤细胞对奥希替尼更敏感

然而治疗过程中往往伴随着抗药性的产生,相关的耐药机制尚不清楚。因此,该研究旨在通过分析EGFR-TKIs初始治疗后的相关耐药性机制,开发出新颖的起始疗法来防止获得性耐药的产生并进一步改善EGFR突变型NSCLC晚期患者的预后。

奥希替尼诱导FOXA1和IGF-1R表达的潜在机制示意图

研究人员发现在EGFR突变型肺癌(EGFRmut-LC)细胞中,AXL低表达水平的细胞相比于AXL高表达水平细胞对奥希替尼更具敏感性,但在少数人群中出现了奥希替尼耐药性。该耐药性是由IGF-1R(胰岛素样生长因子-1受体)表达水平和磷酸化水平上调所引起的,而转录因子FOXA1调控该受体的表达和磷酸化。

IGF-1R与EGFR和衔接蛋白相互作用

研究人员发现,采用奥希替尼治疗时,IGF-1R可与EGFR和衔接蛋白(包括Gab1和IRS1)相互作用并恢复生存信号。移植瘤实验显示,瞬时抑制IGF-1R结合持续的奥希替尼治疗可以根除肿瘤并预防肿瘤的再生,该预防作用后一直持续至停药后。


综上,该研究结果显示奥希替尼治疗时配合适当的抑制耐药信号可显著改善EGFR突变型肺癌的预后。


原始出处:

Wang, R., Yamada, T., Kita, K. et al. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat Commun 11, 4607 (14 September 2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884666, encodeId=46f11884666d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 05:47:12 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041408, encodeId=076b20414089e, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 11 00:47:12 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534519, encodeId=0faa15345198c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Sep 21 08:47:12 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087777, encodeId=2ad0208e7776f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 15 08:47:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886746, encodeId=55bf886e4613, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a><a href='/topic/show?id=e0e2803e878' target=_blank style='color:#2F92EE;'>#耐药性#</a><a href='/topic/show?id=b0c8659869' target=_blank style='color:#2F92EE;'>#EGFR突变肺癌#</a>这是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99387, encryptionId=32af9938ec6, topicName=非小细胞肺癌), TopicDto(id=80378, encryptionId=e0e2803e878, topicName=耐药性), TopicDto(id=6598, encryptionId=b0c8659869, topicName=EGFR突变肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Sep 19 23:20:44 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886724, encodeId=f798886e24c5, content=奥希替尼治疗时配合适当的抑制耐药信号可显著改善EGFR突变型肺癌的预后<a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奥西替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44573, encryptionId=14c0445e37f, topicName=奥西替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sat Sep 19 22:28:12 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
    2020-11-02 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884666, encodeId=46f11884666d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 05:47:12 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041408, encodeId=076b20414089e, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 11 00:47:12 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534519, encodeId=0faa15345198c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Sep 21 08:47:12 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087777, encodeId=2ad0208e7776f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 15 08:47:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886746, encodeId=55bf886e4613, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a><a href='/topic/show?id=e0e2803e878' target=_blank style='color:#2F92EE;'>#耐药性#</a><a href='/topic/show?id=b0c8659869' target=_blank style='color:#2F92EE;'>#EGFR突变肺癌#</a>这是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99387, encryptionId=32af9938ec6, topicName=非小细胞肺癌), TopicDto(id=80378, encryptionId=e0e2803e878, topicName=耐药性), TopicDto(id=6598, encryptionId=b0c8659869, topicName=EGFR突变肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Sep 19 23:20:44 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886724, encodeId=f798886e24c5, content=奥希替尼治疗时配合适当的抑制耐药信号可显著改善EGFR突变型肺癌的预后<a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奥西替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44573, encryptionId=14c0445e37f, topicName=奥西替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sat Sep 19 22:28:12 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884666, encodeId=46f11884666d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 05:47:12 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041408, encodeId=076b20414089e, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 11 00:47:12 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534519, encodeId=0faa15345198c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Sep 21 08:47:12 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087777, encodeId=2ad0208e7776f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 15 08:47:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886746, encodeId=55bf886e4613, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a><a href='/topic/show?id=e0e2803e878' target=_blank style='color:#2F92EE;'>#耐药性#</a><a href='/topic/show?id=b0c8659869' target=_blank style='color:#2F92EE;'>#EGFR突变肺癌#</a>这是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99387, encryptionId=32af9938ec6, topicName=非小细胞肺癌), TopicDto(id=80378, encryptionId=e0e2803e878, topicName=耐药性), TopicDto(id=6598, encryptionId=b0c8659869, topicName=EGFR突变肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Sep 19 23:20:44 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886724, encodeId=f798886e24c5, content=奥希替尼治疗时配合适当的抑制耐药信号可显著改善EGFR突变型肺癌的预后<a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奥西替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44573, encryptionId=14c0445e37f, topicName=奥西替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sat Sep 19 22:28:12 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
    2020-09-21 医者仁心
  4. [GetPortalCommentsPageByObjectIdResponse(id=1884666, encodeId=46f11884666d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 05:47:12 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041408, encodeId=076b20414089e, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 11 00:47:12 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534519, encodeId=0faa15345198c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Sep 21 08:47:12 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087777, encodeId=2ad0208e7776f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 15 08:47:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886746, encodeId=55bf886e4613, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a><a href='/topic/show?id=e0e2803e878' target=_blank style='color:#2F92EE;'>#耐药性#</a><a href='/topic/show?id=b0c8659869' target=_blank style='color:#2F92EE;'>#EGFR突变肺癌#</a>这是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99387, encryptionId=32af9938ec6, topicName=非小细胞肺癌), TopicDto(id=80378, encryptionId=e0e2803e878, topicName=耐药性), TopicDto(id=6598, encryptionId=b0c8659869, topicName=EGFR突变肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Sep 19 23:20:44 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886724, encodeId=f798886e24c5, content=奥希替尼治疗时配合适当的抑制耐药信号可显著改善EGFR突变型肺癌的预后<a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奥西替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44573, encryptionId=14c0445e37f, topicName=奥西替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sat Sep 19 22:28:12 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
    2021-06-15 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=1884666, encodeId=46f11884666d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 05:47:12 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041408, encodeId=076b20414089e, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 11 00:47:12 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534519, encodeId=0faa15345198c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Sep 21 08:47:12 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087777, encodeId=2ad0208e7776f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 15 08:47:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886746, encodeId=55bf886e4613, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a><a href='/topic/show?id=e0e2803e878' target=_blank style='color:#2F92EE;'>#耐药性#</a><a href='/topic/show?id=b0c8659869' target=_blank style='color:#2F92EE;'>#EGFR突变肺癌#</a>这是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99387, encryptionId=32af9938ec6, topicName=非小细胞肺癌), TopicDto(id=80378, encryptionId=e0e2803e878, topicName=耐药性), TopicDto(id=6598, encryptionId=b0c8659869, topicName=EGFR突变肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Sep 19 23:20:44 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886724, encodeId=f798886e24c5, content=奥希替尼治疗时配合适当的抑制耐药信号可显著改善EGFR突变型肺癌的预后<a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奥西替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44573, encryptionId=14c0445e37f, topicName=奥西替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sat Sep 19 22:28:12 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1884666, encodeId=46f11884666d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Nov 02 05:47:12 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041408, encodeId=076b20414089e, content=<a href='/topic/show?id=baade55002a' target=_blank style='color:#2F92EE;'>#突变型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75500, encryptionId=baade55002a, topicName=突变型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jul 11 00:47:12 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534519, encodeId=0faa15345198c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Sep 21 08:47:12 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087777, encodeId=2ad0208e7776f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Jun 15 08:47:12 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886746, encodeId=55bf886e4613, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a><a href='/topic/show?id=e0e2803e878' target=_blank style='color:#2F92EE;'>#耐药性#</a><a href='/topic/show?id=b0c8659869' target=_blank style='color:#2F92EE;'>#EGFR突变肺癌#</a>这是基础研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=248, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99387, encryptionId=32af9938ec6, topicName=非小细胞肺癌), TopicDto(id=80378, encryptionId=e0e2803e878, topicName=耐药性), TopicDto(id=6598, encryptionId=b0c8659869, topicName=EGFR突变肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sat Sep 19 23:20:44 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886724, encodeId=f798886e24c5, content=奥希替尼治疗时配合适当的抑制耐药信号可显著改善EGFR突变型肺癌的预后<a href='/topic/show?id=14c0445e37f' target=_blank style='color:#2F92EE;'>#奥西替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44573, encryptionId=14c0445e37f, topicName=奥西替尼)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Sat Sep 19 22:28:12 CST 2020, time=2020-09-19, status=1, ipAttribution=)]
    2020-09-19 Nebula-Qin

    奥希替尼治疗时配合适当的抑制耐药信号可显著改善EGFR突变型肺癌的预后#奥西替尼#

    0

相关资讯

NEJM:Tabrecta治疗METex14跳跃的非小细胞肺癌,关键研究取得积极结果

MET是由MET基因编码的受体酪氨酸激酶,通常在细胞信号传导、增殖和存活中起重要作用。

Genome Med:武大孙承操等揭示LINC00301在非小细胞肺癌进展和肿瘤免疫中的重要作用

非小细胞肺癌(NSCLC)是全球癌症死亡的首要诱因,然而其发生进展的具体机制仍然需要进一步阐明。长链非编码RNA(lncRNA)是一类长度大于200个核苷酸单位(nt)的不具备完整蛋白编码能力的RNA

NEJM:Tepotinib治疗MET外显子14跳跃突变非小细胞肺癌II期临床效果显著

对于MET外显子14跳跃突变的晚期非小细胞肺癌患者,Tepotinib治疗应答率在50%左右,最常见的3级以上不良事件为外周水肿

Genome Medicine :揭示非编码RNA在非小细胞肺癌进展和肿瘤免疫中的重要作用

长的非编码RNA(lncRNA)在各种癌症类型的肿瘤发生和转移中极为复杂。尽管如此,lncRNA在非小细胞肺癌(NSCLC)中的详细分子机制仍不是不确定。

FDA批准Gavreto(pralsetinib)治疗转移性RET融合阳性非小细胞肺癌

罗氏集团成员Genentech今天宣布,美国食品药品监督管理局(FDA)已批准Gavreto™(pralsetinib)用于治疗转移性RET融合阳性非小细胞肺癌(NSCLC)患者。

NEJM:Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗

对于RET融合阳性非小细胞肺癌患者,Selpercatinib具有显著且持久的疗效

Baidu
map
Baidu
map
Baidu
map